Gilead and Novo Nordisk Present Proof-of-Concept Data for the First Possible NASH Treatment
On November 15th, Gilead Sciences and Novo Nordisk presented results for the Phase 2 proof-of-concept trial for their triple-drug regimen to treat non-alcoholic steatohepatitis (NASH), the most severe form of …
Read More